Adboud Umc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 - 13 March 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a "Game Changing" oral session. Game Changing sessions are reserved for Phase III trials or other developments that the EAU's Scientific Congress Office believes will have a large impact on daily practice. In addition, presentations will report on the potential utility of TLX250-CDx in urothelial carcinoma or bladder cancer (ZiPUP study, ClinicalTrials.gov Identifier: NCT05046665); and a preclinical evaluation of a ....

Noord Brabant , United States , United Kingdom , Kyahn Williamson , Colin Hayward , Peter Mulders , European Association Of Urology , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , University Of Western Australia , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Scientific Congress Office , Health Canada , Pharmaceuticals Limited , Annual European Association , Congress Office , Telix Chief Medical Officer , Professor Peter Mulders , Game Changing , Clinical Trials , Urothelial Cancer Patients , Western Australia , Telix Pharmaceuticals Limited ,